Andros Pharmaceuticals Co (ROCO:6917) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6917 Andros Pharmaceuticals Co Ltd ROCO:6917
41 GF Score
Price NT$34.50
GF Value NT$165.02
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Andros Pharmaceuticals Co Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ROCO:6917 vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Andros Pharmaceuticals Co's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Andros Pharmaceuticals Co Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's Short Interest distribution charts can be found below:

* The bar in red indicates where Andros Pharmaceuticals Co's Short Interest falls into.


ROCO:6917
41GF Score
Andros Pharmaceuticals Co Ltd ROCO:6917
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?

Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$34.50 is trading 79.1% below its estimated GF Value™ of NT$165.02. GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.

Key valuation signals for ROCO:6917:

  • Short Interest:
  • GF Value™: NT$165.02 vs. price of NT$34.50 (79.1% below fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Andros Pharmaceuticals Co Business Description

Address No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
41GF Score

Get the complete analysis for ROCO:6917

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$34.50
Price
NT$165.02
GF Value